Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 12/20 | 0.66 |
| ▸ | DRD5 | P21918 | 5/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | APLNR | P35414 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 1/20 | 0.61 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odapipam SCHEMBL7207803 | 1.00 | DRD1 (0.66) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| Odapipam SCHEMBL1230030 | 0.95 | DRD1 (0.60) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL10695137 | 0.94 | DRD1 (0.64) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL9404411 | 0.87 | DRD1 (0.52) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL8911525 | 0.86 | DRD1 (0.58) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL8911123 | 0.85 | DRD1 (0.55) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL31257120 | 0.84 | DRD1 (0.45) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL8911502 | 0.84 | DRD1 (0.56) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| SCHEMBL8911122 | 0.84 | DRD1 (0.56) | DRD1DRD5DRD2CYP1A2CYP2D6 | |
| Berupipam SCHEMBL7797350 | 0.84 | DRD1 (0.56) | DRD1DRD5DRD2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024136579-A1 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING COGNITIVE DYSFUNCTION, CONTAINING DOPAMINE PRODUCTION INHIBITOR OR DOPAMINE RECEPTOR ANTAGONIST | 서울대학교산학협력단 | 2024-06-27 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20250340671-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING THE NEUROMODULATORY EFFECT OF COCAINE | UNIVERSITY OF CINCINNATI (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2024136579-A1 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING COGNITIVE DYSFUNCTION, CONTAINING DOPAMINE PRODUCTION INHIBITOR OR DOPAMINE RECEPTOR ANTAGONIST | 서울대학교산학협력단 | 2024-06-27 | — | — | WO | disclosed |
| US-20220290159-A1 | miRNAS FOR REDUCING VENTRICLE ENLARGEMENT | St. Jude Children's Research Hpspital, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-1411901-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011255-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-02-13 | — | — | WO | disclosed |
| US-5760216-A | REACTING DRUG SAMPLE WITH SYNTHETIC METALLOPORPHYRIN, OXIDIZING AGENT, SOLVENT TO FORM OXIDATION PRODUCT | ABBOTT LABORATORIES (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0781261-A2 | USE OF SYNTHETIC METALLOPORPHYRINS FOR PREPARATION AND PREDICTION OF DRUG METABOLITES | Abbott Laboratories (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008455-A2 | USE OF SYNTHETIC METALLOPORPHYRINS FOR PREPARATION AND PREDICTION OF DRUG METABOLITES | ABBOTT LABORATORIES (US) | 1996-03-21 | — | — | WO | disclosed |